FDA warned STC India over insanitary conditions and missing Salmonella controls for ready-to-eat mukhwas.
What happened
FDA inspected the Mumbai food facility on January 12-17, 2023 and issued a Form 483 (inspection observations) listing deviations. Investigators found apparent rodent excreta pellets in storage areas and in the attic where Fresh Mint Mukhwas are manufactured, along with dirty equipment and clutter. FDA said the hazard analysis did not treat Salmonella in seeds and spices as requiring control steps and lacked process or supplier controls.
What FDA found
The hazard analysis did not identify Salmonella in seeds and spices as a known or reasonably foreseeable hazard that requires a control step.
21 CFR 117.130(a)(1)The company did not set up a process control step such as a lethal treatment to control Salmonella, and did not validate it.
21 CFR 117.135(c)(1); 21 CFR 117.160The company did not have a supply-chain program to verify that seed and spice suppliers controlled Salmonella, including approved suppliers and annual onsite audits unless a written determination allowed otherwise.
21 CFR 117.405(a)(1); 21 CFR 117.410; 21 CFR 117.430(b)Rodent activity and apparent rodent excreta pellets were found in storage rooms, on the terrace, on a glue pad, and in the attic where Fresh Mint Mukhwas are made.
21 CFR 117.35(c)The plant was not kept clean and in repair: bags and drums touched walls, clutter was present, and dried food residue was on equipment including the hopper cover, ribbon blender, fill and seal machine, and bucket elevator.
21 CFR 117.35(a)
What FDA wants
FDA asks STC India to respond in writing within 15 working days from receipt. The response should outline specific corrections, include documentation, explain how recurrence will be prevented, and give a timetable if work will take longer.
Who should pay attention
- brands that import or sell ready-to-eat mukhwas from India
- retailers and distributors of ethnic snacks
- food manufacturers using seeds and spices from suppliers with pest or pathogen risks
This is a summary. Read the original letter on fda.gov.